Combinatorial Chemotherapeutic Efficacy in Non-Hodgkin Lymphoma Can Be Predicted by a Signaling Model of CD20 Pharmacodynamics
Open Access
- 1 April 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 72 (7), 1632-1641
- https://doi.org/10.1158/0008-5472.can-11-2432
Abstract
Combination chemotherapy represents the standard-of-care for non-Hodgkin lymphoma. However, the development of new therapeutic regimens is empirical and this approach cannot be used prospectively to identify novel or optimal drug combinations. Quantitative system pharmacodynamic models could promote the discovery and development of combination regimens based upon first principles. In this study, we developed a mathematical model that integrates temporal patterns of drug exposure, receptor occupancy, and signal transduction to predict the effects of the CD20 agonist rituximab in combination with rhApo2L/TNF-related apoptosis inducing ligand or fenretinide, a cytotoxic retinoid, upon growth kinetics in non-Hodgkin lymphoma xenografts. The model recapitulated major regulatory mechanisms, including target-mediated disposition of rituximab, modulation of proapoptotic intracellular signaling induced by CD20 occupancy, and the relative efficacy of death receptor isoforms. The multiscale model coupled tumor responses to individual anticancer agents with their mechanisms of action in vivo, and the changes in Bcl-xL and Fas induced by CD20 occupancy were linked to explain the synergy of these drugs. Tumor growth profiles predicted by the model agreed with cell and xenograft data, capturing the apparent pharmacologic synergy of these agents with fidelity. Together, our findings provide a mechanism-based platform for exploring new regimens with CD20 agonists. Cancer Res; 72(7); 1632–41. ©2012 AACR.Other Versions
This publication has 41 references indexed in Scilit:
- The Pharmacokinetic/Pharmacodynamic Pipeline: Translating Anticancer Drug Pharmacology to the ClinicThe AAPS Journal, 2011
- Dysregulation of the cell survival/anti-apoptotic NF-κB pathway by the novel humanized BM-ca anti-CD20 mAb: Implication in chemosensitizationInternational Journal of Oncology, 2009
- Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20Blood, 2009
- Targeting the extrinsic apoptosis pathway in cancerCytokine & Growth Factor Reviews, 2008
- ‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’Oncogene, 2007
- Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosisOncogene, 2007
- The anti‐CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti‐CD19 immunotoxin directed against human B‐cell lymphomaBritish Journal of Haematology, 2006
- Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosisOncogene, 2005
- Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic interventionOncogene, 2005
- Pharmacodynamics of Chemotherapeutic Effects: Dose-Time-Response Relationships for Phase-Nonspecific AgentsJournal of Pharmaceutical Sciences, 1971